D.J. Stewart has a few choice words for glioblastoma, which he’s faced with defiant optimism. Now he’s joining the larger rebellion against brain cancer.
Bruce and Kelly Stahlman found strength in gratitude as they raised, and then lost, twin boys with disabilities. They have faced Bruce’s glioblastoma with the same relentless spirit.
After his glioblastoma diagnosis, Justin Charrette was overwhelmed, physically and mentally. With help from his wife, Courtney, he is feeling stronger and more hopeful about the future.
When glioblastoma led to his early retirement, Wade Lewis put his energy into helping others affected by the same diagnosis.
Following his glioblastoma diagnosis, Steve Davis learned how to savor both the singular and mundane moments of life.
Ira and Sandy Bornstein have always lived an active lifestyle. Since Ira’s glioblastoma diagnosis, they have stayed committed to doing what they love most.
Lynn Oxenberg is used to standing out in a crowd. Since her glioblastoma diagnosis, she has used her influence to help others affected by brain tumors.
After her second son was born, Nikki Woolfolk began experiencing panic-like anxiety. Despite medical care and therapy, her symptoms persisted. Her primary care physician referred her to a neurologist, who ordered an MRI. The results showed a tumor in her brain.
emboldened to innovate
Novocure created a new way to treat some of the most aggressive forms of cancer. Six employees share how they harness our founding spirit to deliver innovative solutions.
acting with empathy
We put ourselves in the shoes of our patients, their families, health care providers, researchers and our colleagues as we strive to change the way cancer is treated. Six Novocure employees share their stories of empathy.
honing our focus
To achieve our patient-forward aspirations, we must be intentional in how we spend our time, energy and resources. Six Novocure employees share their strategies for focus.
calling on courage
We stand alongside our patients and stand up for them by challenging the status quo. Six Novocure employees share their stories of courage.
Our dedication to developing and maintaining trusting relationships helps us make a difference in the lives of cancer patients. Six Novocure employees share how they build trust.
driven to make an impact
Our passion for making a difference in the lives of cancer patients fuels us in our work and guides us in our decision-making. Six Novocure employees share their stories of drive.
Our Global Supply Chain team is building the backbone for our anticipated growth.
Novocure named a top workplace in New Hampshire
Novocure, a global oncology company with U.S. operations based in New Hampshire, has been recognized as a top employer in the Granite State for the second year in a row.
you are not alone in facing a cancer diagnosis
Lean on patient advocacy groups for the support you need.
a Q&A with our founder
Novocure founder Professor Yoram Palti, recipient of the 2022 Israel Prize for excellence in entrepreneurship and technological innovation, reflects on his discovery of Tumor Treating Fields.
Novocure pledges $250K to Families First Health and Support Center
We committed the lead corporate gift to the capital campaign for a New Hampshire community health center’s new home.
lighting the world blue
Mesothelioma Awareness Day takes place annually in the U.S. on Sept. 26.
standing with the brain tumor community
As a global oncology company focusing on improving survival in some of the most aggressive forms of cancer, Novocure proudly stands with the brain tumor community during May for Brain Tumor Awareness Month (BTAM).
Ignace Vergote, Novocure Clinical Trial Investigator
Professor Ignace Vergote has dedicated his 32-year career to investigating treatment options and striving to improve survival in gynecologic cancers. Among gynecologic cancers, ovarian cancer is the deadliest, representing the fifth most common cause of cancer death among women in the United States. Five-year survival in ovarian cancer has slowly increased from 34 percent in 1975 to 47 percent today.